SAM App for Medication Adherence
Trial Summary
What is the purpose of this trial?
Introduction: Almost half of patients discharged from hospital are re-admitted or return to the emergency department (ED) within 90 days. Patient nonadherence to medication changes during hospitalization and the use of potentially inappropriate medications (PIMs) both contribute to the risk of adverse events post-discharge. Smart About Meds (SAM) is a patient-centered mobile application designed to target medication nonadherence and PIMs use. This protocol describes a randomized controlled trial (RCT) to evaluate the effectiveness of SAM. Methods \& Analysis: A pragmatic, stratified RCT will be conducted among 3,250 patients discharged from internal medicine, cardiac care, cardiac surgery, vascular surgery, and respiratory units of the Royal Victoria Hospital and the Montreal General Hospital. At discharge, patients will be randomized 1:1 to usual care or the SAM intervention. SAM integrates novel user-centered features (e.g. continuously updated medication list with pill images, side-effect checker, interaction checker) with pharmacist monitoring to tackle post-discharge nonadherence to new medication regimens. SAM also notifies patients of PIMS in their regimen, with advice to discuss with their physician. Following discharge, patients will be followed for 90 days, during which the occurrence of the composite outcome of ED visits, hospital readmissions, or death will be measured. Secondary outcomes will include the individual components of the composite outcome, nonadherence to medication changes, defined as failure to fill a new prescription, filling a modified prescription at the incorrect dose, or filling discontinued medications, secondary medication adherence, patient empowerment, and health-related quality of life. An intention-to-treat analysis will evaluate the effectiveness of SAM. Multivariable logistic regression will estimate differences between treatment groups in the proportion of patients nonadherent to at least one medication change. With a sample size of 3,250, there will be 80% power to detect a 5% absolute reduction in this outcome. Two-way interaction terms will test hypothesized modifiers of SAM's effectiveness, including hospital, unit, age, sex, gender and comorbidity burden. Binary and continuous secondary outcomes will be assessed using multivariable logistic and linear regression, respectively.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. It focuses on helping you manage your medications better after being discharged from the hospital.
What data supports the effectiveness of the SAM App treatment for medication adherence?
Research suggests that mobile applications, like the SAM App, can help people stick to their medication schedules, especially for those with long-term health conditions. A pilot study of the SAM App showed it might improve how well people follow their medication plans after leaving the hospital.12345
Is the SAM App for Medication Adherence safe for humans?
The pilot study of the Smart About Meds (SAM) app aimed to evaluate its potential to improve medication adherence and monitor adverse events, but specific safety data is not detailed in the available research. Additionally, a broader review of medication adherence apps highlighted concerns about data security and privacy, suggesting that none of the apps, including SAM, have undergone certification for safety and should not be recommended by healthcare providers without further clinical studies.14567
How is the SAM app treatment different from other treatments for medication adherence?
The SAM app is unique because it is a mobile application designed to help patients manage their medications after leaving the hospital, focusing on improving adherence to medication changes. Unlike traditional methods, it offers a patient-centered, scalable, and potentially more effective way to support medication adherence through technology.148910
Eligibility Criteria
The SAM trial is for patients who speak English or French, have provincial health and prescription insurance, own a smart device with internet, and had a medication change at hospital discharge. It excludes those sent to rehab or transferred to non-study units.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Patients receive training in and access to the SAM app at discharge, which includes features like medication list updates, adherence alerts, and pharmacist connect.
Follow-up
Participants are monitored for the occurrence of ED visits, hospital readmissions, or death, as well as secondary outcomes like medication adherence and quality of life.
Data Analysis
Intention-to-treat analysis and multivariable logistic regression to evaluate the effectiveness of SAM.
Treatment Details
Interventions
- Smart About Meds (SAM) mobile application
Smart About Meds (SAM) mobile application is already approved in Canada for the following indications:
- Medication adherence support
Find a Clinic Near You
Who Is Running the Clinical Trial?
Robyn Tamblyn
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator